Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium

Liza C. Villaruz, Mark A. Socinski, Shira Abberbock, Lynne D. Berry, Bruce E. Johnson, David J. Kwiatkowski, A. John Iafrate, Marileila Varella-Garcia, Wilbur A. Franklin, D. Ross Camidge, Lecia V. Sequist, Eric B. Haura, Mark Ladanyi, Brenda F. Kurland, Kelly Kugler, John D. Minna, Paul A. Bunn, Mark G. Kris

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

BACKGROUND: The advent of effective targeted therapy for BRAFV600E-mutant lung adenocarcinomas necessitates further exploration of the unique clinical features and behavior of advanced-stage BRAF-mutant lung adenocarcinomas. METHODS: Data were reviewed for patients with advanced lung adenocarcinomas enrolled in the Lung Cancer Mutation Consortium whose tumors underwent testing for mutations in epidermal growth factor receptor ( EGFR), Kirsten rat sarcoma viral oncogene homolog (KRAS), human epidermal growth factor receptor 2 ( HER2), AKT1, BRAF, dual-specificity mitogen-activated protein kinase kinase 1 ( MEK1), neuroblastoma RAS viral (v-ras) oncogene homolog (NRAS), and phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit a (PIK3CA); for anaplastic lymphoma kinase (ALK) translocations; and for MET amplification. RESULTS: Twenty-one BRAF mutations were identified in 951 patients with adenocarcinomas (2.2%; 95% confidence interval [CI], 1.4%-3.4%): 17 (81%; 95% CI, 60%-92%) were BRAFV600E mutations, and 4 were non-BRAFV600E mutations. Among the 733 cases tested for all 10 genes, BRAF mutations were more likely to occur than most other genotypic abnormalities in current or former smokers (BRAF vs sensitizing EGFR, 82% vs 36%, mid-P < .001; BRAF vs ALK, 39%, mid-P = .003; BRAF vs other mutations, 49%, mid-P = .02; BRAF vs patients with more than 1 oncogenic driver [doubleton], 46%, mid-P = .04.) The double-mutation rate was 16% among patients with BRAF mutations but 5% among patients with other genomic abnormalities (mid-P = .045). Differences were not found in survival between patients with BRAF mutations and those with other genomic abnormalities (P > .20). CONCLUSIONS: BRAF mutations occurred in 2.2% of advanced-stage lung adenocarcinomas, were most commonly V600E, and were associated with distinct clinicopathologic features in comparison with other genomic subtypes and with a high mutation rate in more than 1 gene. These findings underscore the importance of comprehensive genomic profiling in assessing patients with advanced lung adenocarcinomas.

Original languageEnglish (US)
Pages (from-to)448-456
Number of pages9
JournalCancer
Volume121
Issue number3
DOIs
StatePublished - Feb 1 2015

Fingerprint

Lung Neoplasms
Mutation
MAP Kinase Kinase 1
Confidence Intervals
ras Genes
Mutation Rate
Adenocarcinoma of lung
Neuroblastoma
Oncogenes
Epidermal Growth Factor Receptor
Sarcoma
Genes
Catalytic Domain
Adenocarcinoma
Neoplasms

Keywords

  • BRAF
  • Clinicopathologic features
  • Genomic profiling
  • Lung adenocarcinomas
  • Lung Cancer Mutation Consortium

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Villaruz, L. C., Socinski, M. A., Abberbock, S., Berry, L. D., Johnson, B. E., Kwiatkowski, D. J., ... Kris, M. G. (2015). Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium. Cancer, 121(3), 448-456. https://doi.org/10.1002/cncr.29042

Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium. / Villaruz, Liza C.; Socinski, Mark A.; Abberbock, Shira; Berry, Lynne D.; Johnson, Bruce E.; Kwiatkowski, David J.; John Iafrate, A.; Varella-Garcia, Marileila; Franklin, Wilbur A.; Camidge, D. Ross; Sequist, Lecia V.; Haura, Eric B.; Ladanyi, Mark; Kurland, Brenda F.; Kugler, Kelly; Minna, John D.; Bunn, Paul A.; Kris, Mark G.

In: Cancer, Vol. 121, No. 3, 01.02.2015, p. 448-456.

Research output: Contribution to journalArticle

Villaruz, LC, Socinski, MA, Abberbock, S, Berry, LD, Johnson, BE, Kwiatkowski, DJ, John Iafrate, A, Varella-Garcia, M, Franklin, WA, Camidge, DR, Sequist, LV, Haura, EB, Ladanyi, M, Kurland, BF, Kugler, K, Minna, JD, Bunn, PA & Kris, MG 2015, 'Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium', Cancer, vol. 121, no. 3, pp. 448-456. https://doi.org/10.1002/cncr.29042
Villaruz, Liza C. ; Socinski, Mark A. ; Abberbock, Shira ; Berry, Lynne D. ; Johnson, Bruce E. ; Kwiatkowski, David J. ; John Iafrate, A. ; Varella-Garcia, Marileila ; Franklin, Wilbur A. ; Camidge, D. Ross ; Sequist, Lecia V. ; Haura, Eric B. ; Ladanyi, Mark ; Kurland, Brenda F. ; Kugler, Kelly ; Minna, John D. ; Bunn, Paul A. ; Kris, Mark G. / Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium. In: Cancer. 2015 ; Vol. 121, No. 3. pp. 448-456.
@article{772fe5ab85b04178bfc8b3e6646679d0,
title = "Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium",
abstract = "BACKGROUND: The advent of effective targeted therapy for BRAFV600E-mutant lung adenocarcinomas necessitates further exploration of the unique clinical features and behavior of advanced-stage BRAF-mutant lung adenocarcinomas. METHODS: Data were reviewed for patients with advanced lung adenocarcinomas enrolled in the Lung Cancer Mutation Consortium whose tumors underwent testing for mutations in epidermal growth factor receptor ( EGFR), Kirsten rat sarcoma viral oncogene homolog (KRAS), human epidermal growth factor receptor 2 ( HER2), AKT1, BRAF, dual-specificity mitogen-activated protein kinase kinase 1 ( MEK1), neuroblastoma RAS viral (v-ras) oncogene homolog (NRAS), and phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit a (PIK3CA); for anaplastic lymphoma kinase (ALK) translocations; and for MET amplification. RESULTS: Twenty-one BRAF mutations were identified in 951 patients with adenocarcinomas (2.2{\%}; 95{\%} confidence interval [CI], 1.4{\%}-3.4{\%}): 17 (81{\%}; 95{\%} CI, 60{\%}-92{\%}) were BRAFV600E mutations, and 4 were non-BRAFV600E mutations. Among the 733 cases tested for all 10 genes, BRAF mutations were more likely to occur than most other genotypic abnormalities in current or former smokers (BRAF vs sensitizing EGFR, 82{\%} vs 36{\%}, mid-P < .001; BRAF vs ALK, 39{\%}, mid-P = .003; BRAF vs other mutations, 49{\%}, mid-P = .02; BRAF vs patients with more than 1 oncogenic driver [doubleton], 46{\%}, mid-P = .04.) The double-mutation rate was 16{\%} among patients with BRAF mutations but 5{\%} among patients with other genomic abnormalities (mid-P = .045). Differences were not found in survival between patients with BRAF mutations and those with other genomic abnormalities (P > .20). CONCLUSIONS: BRAF mutations occurred in 2.2{\%} of advanced-stage lung adenocarcinomas, were most commonly V600E, and were associated with distinct clinicopathologic features in comparison with other genomic subtypes and with a high mutation rate in more than 1 gene. These findings underscore the importance of comprehensive genomic profiling in assessing patients with advanced lung adenocarcinomas.",
keywords = "BRAF, Clinicopathologic features, Genomic profiling, Lung adenocarcinomas, Lung Cancer Mutation Consortium",
author = "Villaruz, {Liza C.} and Socinski, {Mark A.} and Shira Abberbock and Berry, {Lynne D.} and Johnson, {Bruce E.} and Kwiatkowski, {David J.} and {John Iafrate}, A. and Marileila Varella-Garcia and Franklin, {Wilbur A.} and Camidge, {D. Ross} and Sequist, {Lecia V.} and Haura, {Eric B.} and Mark Ladanyi and Kurland, {Brenda F.} and Kelly Kugler and Minna, {John D.} and Bunn, {Paul A.} and Kris, {Mark G.}",
year = "2015",
month = "2",
day = "1",
doi = "10.1002/cncr.29042",
language = "English (US)",
volume = "121",
pages = "448--456",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "3",

}

TY - JOUR

T1 - Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium

AU - Villaruz, Liza C.

AU - Socinski, Mark A.

AU - Abberbock, Shira

AU - Berry, Lynne D.

AU - Johnson, Bruce E.

AU - Kwiatkowski, David J.

AU - John Iafrate, A.

AU - Varella-Garcia, Marileila

AU - Franklin, Wilbur A.

AU - Camidge, D. Ross

AU - Sequist, Lecia V.

AU - Haura, Eric B.

AU - Ladanyi, Mark

AU - Kurland, Brenda F.

AU - Kugler, Kelly

AU - Minna, John D.

AU - Bunn, Paul A.

AU - Kris, Mark G.

PY - 2015/2/1

Y1 - 2015/2/1

N2 - BACKGROUND: The advent of effective targeted therapy for BRAFV600E-mutant lung adenocarcinomas necessitates further exploration of the unique clinical features and behavior of advanced-stage BRAF-mutant lung adenocarcinomas. METHODS: Data were reviewed for patients with advanced lung adenocarcinomas enrolled in the Lung Cancer Mutation Consortium whose tumors underwent testing for mutations in epidermal growth factor receptor ( EGFR), Kirsten rat sarcoma viral oncogene homolog (KRAS), human epidermal growth factor receptor 2 ( HER2), AKT1, BRAF, dual-specificity mitogen-activated protein kinase kinase 1 ( MEK1), neuroblastoma RAS viral (v-ras) oncogene homolog (NRAS), and phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit a (PIK3CA); for anaplastic lymphoma kinase (ALK) translocations; and for MET amplification. RESULTS: Twenty-one BRAF mutations were identified in 951 patients with adenocarcinomas (2.2%; 95% confidence interval [CI], 1.4%-3.4%): 17 (81%; 95% CI, 60%-92%) were BRAFV600E mutations, and 4 were non-BRAFV600E mutations. Among the 733 cases tested for all 10 genes, BRAF mutations were more likely to occur than most other genotypic abnormalities in current or former smokers (BRAF vs sensitizing EGFR, 82% vs 36%, mid-P < .001; BRAF vs ALK, 39%, mid-P = .003; BRAF vs other mutations, 49%, mid-P = .02; BRAF vs patients with more than 1 oncogenic driver [doubleton], 46%, mid-P = .04.) The double-mutation rate was 16% among patients with BRAF mutations but 5% among patients with other genomic abnormalities (mid-P = .045). Differences were not found in survival between patients with BRAF mutations and those with other genomic abnormalities (P > .20). CONCLUSIONS: BRAF mutations occurred in 2.2% of advanced-stage lung adenocarcinomas, were most commonly V600E, and were associated with distinct clinicopathologic features in comparison with other genomic subtypes and with a high mutation rate in more than 1 gene. These findings underscore the importance of comprehensive genomic profiling in assessing patients with advanced lung adenocarcinomas.

AB - BACKGROUND: The advent of effective targeted therapy for BRAFV600E-mutant lung adenocarcinomas necessitates further exploration of the unique clinical features and behavior of advanced-stage BRAF-mutant lung adenocarcinomas. METHODS: Data were reviewed for patients with advanced lung adenocarcinomas enrolled in the Lung Cancer Mutation Consortium whose tumors underwent testing for mutations in epidermal growth factor receptor ( EGFR), Kirsten rat sarcoma viral oncogene homolog (KRAS), human epidermal growth factor receptor 2 ( HER2), AKT1, BRAF, dual-specificity mitogen-activated protein kinase kinase 1 ( MEK1), neuroblastoma RAS viral (v-ras) oncogene homolog (NRAS), and phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit a (PIK3CA); for anaplastic lymphoma kinase (ALK) translocations; and for MET amplification. RESULTS: Twenty-one BRAF mutations were identified in 951 patients with adenocarcinomas (2.2%; 95% confidence interval [CI], 1.4%-3.4%): 17 (81%; 95% CI, 60%-92%) were BRAFV600E mutations, and 4 were non-BRAFV600E mutations. Among the 733 cases tested for all 10 genes, BRAF mutations were more likely to occur than most other genotypic abnormalities in current or former smokers (BRAF vs sensitizing EGFR, 82% vs 36%, mid-P < .001; BRAF vs ALK, 39%, mid-P = .003; BRAF vs other mutations, 49%, mid-P = .02; BRAF vs patients with more than 1 oncogenic driver [doubleton], 46%, mid-P = .04.) The double-mutation rate was 16% among patients with BRAF mutations but 5% among patients with other genomic abnormalities (mid-P = .045). Differences were not found in survival between patients with BRAF mutations and those with other genomic abnormalities (P > .20). CONCLUSIONS: BRAF mutations occurred in 2.2% of advanced-stage lung adenocarcinomas, were most commonly V600E, and were associated with distinct clinicopathologic features in comparison with other genomic subtypes and with a high mutation rate in more than 1 gene. These findings underscore the importance of comprehensive genomic profiling in assessing patients with advanced lung adenocarcinomas.

KW - BRAF

KW - Clinicopathologic features

KW - Genomic profiling

KW - Lung adenocarcinomas

KW - Lung Cancer Mutation Consortium

UR - http://www.scopus.com/inward/record.url?scp=84921473873&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84921473873&partnerID=8YFLogxK

U2 - 10.1002/cncr.29042

DO - 10.1002/cncr.29042

M3 - Article

VL - 121

SP - 448

EP - 456

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 3

ER -